Compare WAL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAL | AXSM |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | WAL | AXSM |
|---|---|---|
| Price | $91.20 | $185.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $101.40 | ★ $201.76 |
| AVG Volume (30 Days) | ★ 1.1M | 498.9K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.16 | $67.87 |
| Revenue Next Year | $8.63 | $58.77 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $86.99 |
| 52 Week High | $97.23 | $191.50 |
| Indicator | WAL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 58.94 |
| Support Level | $91.80 | $180.40 |
| Resistance Level | $96.51 | $186.04 |
| Average True Range (ATR) | 3.31 | 4.87 |
| MACD | -0.15 | -1.06 |
| Stochastic Oscillator | 35.97 | 58.86 |
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.